Clinical Study of Docetaxel, Prednisone and Bevacizunab in the Treatment of Hormone Refractory Prostate Cancer

Clinical Study of Docetaxel, Prednisone and Bevacizunab in the Treatment of Hormone Refractory Prostate Cancer

Objective: To observe the clinical therapeutic effect of docetaxel, prednisone and bevacizunab in the treatment of hormone refractory prostate cancer. Methods: A total of 100 patients with hormone refractory prostate cancer were selected and randomly divided into 2 groups: chemotherapy group and com...

Full description

Bibliographic Details
Main Authors: Theodore D. Koreckij, Todd M. Morgan
Format: Article
Language:English
Published: Third Party Medicine International Publishing Group Co. Limited 2015-06-01
Series:Journal of International Translational Medicine
Subjects:
Prostate cancer
Docetaxel
Bevacizunab
Survival rate
Online Access:http://www.jitm.hk/EN/abstract/abstract142.shtml

Internet

http://www.jitm.hk/EN/abstract/abstract142.shtml

Similar Items